marked.bio

Company

Multitude Therapeutics

2 active trials that select patients by a biomarker on marked.bio; 1 in phase 3.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

ivonescimab 1

Upcoming readouts

Active phase 2 and 3 trials whose primary completion date falls in the next 12 months, according to the sponsor.

Trials

2 of 2 trials shown

  1. Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy

    Recruiting Phase 2/3 Multitude Therapeutics Started 2026Primary completion 2028-03 NCT07718737

    AMT-116

    6.2 Patients with gene mutations that do not routinely use immunotherapy (e.g., ALK fusion): Have experienced disease progression after targeted therapy for gene mutations and plat…

    ALK fusionNSCLC (Advanced Non-small Cell Lung Cancer)

  2. AMT-116 in Combination With AK112 in Patients With Lung Cancer

    Recruiting Phase 1/2 Multitude Therapeutics Started 2026Primary completion 2027-05 NCT07590531

    AMT-116ivonescimab

    …ort 3: Histologically or cytologically diagnosed with non-squamous NSCLC and harboring an EGFR mutation.

    EGFR exon 19 deletion / L858RAdvanced Non-small Cell Lung Cancer (NSCLC)